Skip to main content

Senokot S Disease Interactions

There are 4 disease interactions with Senokot S (docusate/senna).

Major

Laxatives (applies to Senokot S) inflammatory bowel disease

Major Potential Hazard, High plausibility.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD
  3. "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb PROD
  4. "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc PROD (2001):
  5. "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
  6. "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
View all 6 references
Major

Laxatives (applies to Senokot S) intestinal obstruction disorders

Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Obstruction, Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD
  3. "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb PROD
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet PROD (2001):
  5. "Product Information. Citrucel (methylcellulose)." SmithKline Beecham PROD (2001):
  6. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc PROD (2001):
  7. "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
  8. "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
View all 8 references
Major

Stimulant laxatives (applies to Senokot S) acute surgical abdomen

Major Potential Hazard, High plausibility. Applicable conditions: Appendicitis

The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis. These patients may be candidates for emergency surgery. Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.

References

  1. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD
  3. "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb PROD
  4. "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
View all 4 references
Major

Stimulant laxatives (applies to Senokot S) rectal bleeding

Major Potential Hazard, Moderate plausibility.

The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures. These preparations may cause irritation, burning sensation, and proctitis.

References

  1. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD

Senokot S drug interactions

There are 217 drug interactions with Senokot S (docusate/senna).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer